Preferential autoimmune response in prostate cancer to cyclin B1 in a panel of tumor-associated antigens. | Profiles RNS

RCMI Coordinating Center (RCMI CC)

Preferential autoimmune response in prostate cancer to cyclin B1 in a panel of tumor-associated antigens.

Dai L, Li J, Ortega R, Qian W, Casiano CA, Zhang JY. Preferential autoimmune response in prostate cancer to cyclin B1 in a panel of tumor-associated antigens. J Immunol Res. 2014; 2014:827827.

View in: PubMed

authors with profiles

Jianying Zhang

RCMI CC is supported by the National Institute on Minority Health and Health Disparities, National Institutes of Health (NIH), through Grant Number U24MD015970. The contents of this site are solely the responsibility of the authors and do not necessarily represent the official views of the NIH

For technical support please contact support